ARS Pharmaceuticals announces planned launch of neffyinSchools

ARS Pharmaceuticals (SPRY) announced that it will be launching the neffyinSchools Program in January 2025. The program will provide eligible public and private K-12 schools in the U.S. the opportunity to receive two cartons of neffy 2mg for use in emergency situations at no cost to the school. neffy 2mg was recently approved for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh greater than or equal to30 kg. Participating schools will be eligible to receive replacement doses when the product is used or expires.